CN114920844B - 一种增强car-t功能的合成纳米抗体及其制备方法和应用 - Google Patents
一种增强car-t功能的合成纳米抗体及其制备方法和应用 Download PDFInfo
- Publication number
- CN114920844B CN114920844B CN202210733760.8A CN202210733760A CN114920844B CN 114920844 B CN114920844 B CN 114920844B CN 202210733760 A CN202210733760 A CN 202210733760A CN 114920844 B CN114920844 B CN 114920844B
- Authority
- CN
- China
- Prior art keywords
- antibody
- binding
- human
- protein
- antibodies
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000002708 enhancing effect Effects 0.000 title abstract description 8
- 238000002360 preparation method Methods 0.000 title abstract description 7
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims abstract description 94
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims abstract description 93
- 238000009739 binding Methods 0.000 claims description 31
- 230000027455 binding Effects 0.000 claims description 29
- 102000004473 OX40 Ligand Human genes 0.000 claims description 16
- 108010042215 OX40 Ligand Proteins 0.000 claims description 16
- 238000012360 testing method Methods 0.000 claims description 14
- 230000005764 inhibitory process Effects 0.000 claims description 11
- KGRVJHAUYBGFFP-UHFFFAOYSA-N 2,2'-Methylenebis(4-methyl-6-tert-butylphenol) Chemical compound CC(C)(C)C1=CC(C)=CC(CC=2C(=C(C=C(C)C=2)C(C)(C)C)O)=C1O KGRVJHAUYBGFFP-UHFFFAOYSA-N 0.000 claims description 10
- 238000010276 construction Methods 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 10
- 230000009870 specific binding Effects 0.000 claims description 10
- 102000003945 NF-kappa B Human genes 0.000 claims description 9
- 108010057466 NF-kappa B Proteins 0.000 claims description 9
- 230000019491 signal transduction Effects 0.000 claims description 7
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 claims description 7
- 230000004913 activation Effects 0.000 claims description 6
- 238000000159 protein binding assay Methods 0.000 claims description 6
- 238000002474 experimental method Methods 0.000 claims description 5
- 108700008625 Reporter Genes Proteins 0.000 claims description 3
- 230000003389 potentiating effect Effects 0.000 claims description 3
- 230000008685 targeting Effects 0.000 claims description 3
- 238000003556 assay Methods 0.000 claims description 2
- 238000003030 reporter gene method Methods 0.000 claims description 2
- 230000000259 anti-tumor effect Effects 0.000 abstract description 4
- 210000004027 cell Anatomy 0.000 description 83
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 25
- 206010028980 Neoplasm Diseases 0.000 description 15
- 108090000623 proteins and genes Proteins 0.000 description 15
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical group P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 13
- 239000002953 phosphate buffered saline Substances 0.000 description 13
- 238000012216 screening Methods 0.000 description 12
- 101000679851 Homo sapiens Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 description 11
- 230000006870 function Effects 0.000 description 11
- 235000018102 proteins Nutrition 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 11
- 210000001744 T-lymphocyte Anatomy 0.000 description 10
- 238000001514 detection method Methods 0.000 description 10
- 230000014509 gene expression Effects 0.000 description 10
- 239000000872 buffer Substances 0.000 description 9
- 239000008363 phosphate buffer Substances 0.000 description 9
- 102000050320 human TNFRSF4 Human genes 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 239000006228 supernatant Substances 0.000 description 8
- 238000005406 washing Methods 0.000 description 8
- 239000002504 physiological saline solution Substances 0.000 description 7
- YYSWCHMLFJLLBJ-ZLUOBGJFSA-N Ala-Ala-Ser Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O YYSWCHMLFJLLBJ-ZLUOBGJFSA-N 0.000 description 6
- 238000005119 centrifugation Methods 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 239000013612 plasmid Substances 0.000 description 6
- 239000005089 Luciferase Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000009169 immunotherapy Methods 0.000 description 5
- VKKYFICVTYKFIO-CIUDSAMLSA-N Arg-Ala-Glu Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCN=C(N)N VKKYFICVTYKFIO-CIUDSAMLSA-N 0.000 description 4
- NKBQZKVMKJJDLX-SRVKXCTJSA-N Arg-Glu-Leu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O NKBQZKVMKJJDLX-SRVKXCTJSA-N 0.000 description 4
- ZEBDYGZVMMKZNB-SRVKXCTJSA-N Arg-Met-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCN=C(N)N)N ZEBDYGZVMMKZNB-SRVKXCTJSA-N 0.000 description 4
- SLKLLQWZQHXYSV-CIUDSAMLSA-N Asn-Ala-Lys Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(O)=O SLKLLQWZQHXYSV-CIUDSAMLSA-N 0.000 description 4
- MKJBPDLENBUHQU-CIUDSAMLSA-N Asn-Ser-Leu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O MKJBPDLENBUHQU-CIUDSAMLSA-N 0.000 description 4
- MNQMTYSEKZHIDF-GCJQMDKQSA-N Asp-Thr-Ala Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O MNQMTYSEKZHIDF-GCJQMDKQSA-N 0.000 description 4
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 4
- OYTPNWYZORARHL-XHNCKOQMSA-N Gln-Ala-Pro Chemical compound C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCC(=O)N)N OYTPNWYZORARHL-XHNCKOQMSA-N 0.000 description 4
- FQCILXROGNOZON-YUMQZZPRSA-N Gln-Pro-Gly Chemical compound NC(=O)CC[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O FQCILXROGNOZON-YUMQZZPRSA-N 0.000 description 4
- PXXGVUVQWQGGIG-YUMQZZPRSA-N Glu-Gly-Arg Chemical compound OC(=O)CC[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCCN=C(N)N PXXGVUVQWQGGIG-YUMQZZPRSA-N 0.000 description 4
- YQPFCZVKMUVZIN-AUTRQRHGSA-N Glu-Val-Gln Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O YQPFCZVKMUVZIN-AUTRQRHGSA-N 0.000 description 4
- MIIVFRCYJABHTQ-ONGXEEELSA-N Gly-Leu-Val Chemical compound [H]NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(O)=O MIIVFRCYJABHTQ-ONGXEEELSA-N 0.000 description 4
- PDUHNKAFQXQNLH-ZETCQYMHSA-N Gly-Lys-Gly Chemical compound NCCCC[C@H](NC(=O)CN)C(=O)NCC(O)=O PDUHNKAFQXQNLH-ZETCQYMHSA-N 0.000 description 4
- PMGDADKJMCOXHX-UHFFFAOYSA-N L-Arginyl-L-glutamin-acetat Natural products NC(=N)NCCCC(N)C(=O)NC(CCC(N)=O)C(O)=O PMGDADKJMCOXHX-UHFFFAOYSA-N 0.000 description 4
- AXZGZMGRBDQTEY-SRVKXCTJSA-N Leu-Gln-Met Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCSC)C(O)=O AXZGZMGRBDQTEY-SRVKXCTJSA-N 0.000 description 4
- KIZIOFNVSOSKJI-CIUDSAMLSA-N Leu-Ser-Cys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)O)N KIZIOFNVSOSKJI-CIUDSAMLSA-N 0.000 description 4
- AIMGJYMCTAABEN-GVXVVHGQSA-N Leu-Val-Glu Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O AIMGJYMCTAABEN-GVXVVHGQSA-N 0.000 description 4
- 108060001084 Luciferase Proteins 0.000 description 4
- AJHCSUXXECOXOY-UHFFFAOYSA-N N-glycyl-L-tryptophan Natural products C1=CC=C2C(CC(NC(=O)CN)C(O)=O)=CNC2=C1 AJHCSUXXECOXOY-UHFFFAOYSA-N 0.000 description 4
- FGWUALWGCZJQDJ-URLPEUOOSA-N Phe-Thr-Ile Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O FGWUALWGCZJQDJ-URLPEUOOSA-N 0.000 description 4
- QEDMOZUJTGEIBF-FXQIFTODSA-N Ser-Arg-Asp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(O)=O QEDMOZUJTGEIBF-FXQIFTODSA-N 0.000 description 4
- YMTLKLXDFCSCNX-BYPYZUCNSA-N Ser-Gly-Gly Chemical compound OC[C@H](N)C(=O)NCC(=O)NCC(O)=O YMTLKLXDFCSCNX-BYPYZUCNSA-N 0.000 description 4
- QYSFWUIXDFJUDW-DCAQKATOSA-N Ser-Leu-Arg Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O QYSFWUIXDFJUDW-DCAQKATOSA-N 0.000 description 4
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 4
- SLOYNOMYOAOUCX-BVSLBCMMSA-N Trp-Phe-Arg Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O SLOYNOMYOAOUCX-BVSLBCMMSA-N 0.000 description 4
- OWFGFHQMSBTKLX-UFYCRDLUSA-N Val-Tyr-Tyr Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)O)N OWFGFHQMSBTKLX-UFYCRDLUSA-N 0.000 description 4
- 239000000556 agonist Substances 0.000 description 4
- 108010008685 alanyl-glutamyl-aspartic acid Proteins 0.000 description 4
- 108010069020 alanyl-prolyl-glycine Proteins 0.000 description 4
- 108010086434 alanyl-seryl-glycine Proteins 0.000 description 4
- 108010008355 arginyl-glutamine Proteins 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 238000010494 dissociation reaction Methods 0.000 description 4
- 230000005593 dissociations Effects 0.000 description 4
- 108010067216 glycyl-glycyl-glycine Proteins 0.000 description 4
- XKUKSGPZAADMRA-UHFFFAOYSA-N glycyl-glycyl-glycine Natural products NCC(=O)NCC(=O)NCC(O)=O XKUKSGPZAADMRA-UHFFFAOYSA-N 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 108010020755 prolyl-glycyl-glycine Proteins 0.000 description 4
- 210000003289 regulatory T cell Anatomy 0.000 description 4
- 235000020183 skimmed milk Nutrition 0.000 description 4
- JSHWXQIZOCVWIA-ZKWXMUAHSA-N Asp-Ser-Val Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O JSHWXQIZOCVWIA-ZKWXMUAHSA-N 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- HNAUFGBKJLTWQE-IFFSRLJSSA-N Gln-Val-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCC(=O)N)N)O HNAUFGBKJLTWQE-IFFSRLJSSA-N 0.000 description 3
- VNNRLUNBJSWZPF-ZKWXMUAHSA-N Gly-Ser-Ile Chemical compound [H]NCC(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O VNNRLUNBJSWZPF-ZKWXMUAHSA-N 0.000 description 3
- 241000880493 Leptailurus serval Species 0.000 description 3
- 229930040373 Paraformaldehyde Natural products 0.000 description 3
- KHPLUFDSWGDRHD-SLFFLAALSA-N Tyr-Tyr-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CC3=CC=C(C=C3)O)N)C(=O)O KHPLUFDSWGDRHD-SLFFLAALSA-N 0.000 description 3
- PZTZYZUTCPZWJH-FXQIFTODSA-N Val-Ser-Ser Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)O)N PZTZYZUTCPZWJH-FXQIFTODSA-N 0.000 description 3
- 230000003698 anagen phase Effects 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 229920002866 paraformaldehyde Polymers 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 108010038745 tryptophylglycine Proteins 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- IFKQPMZRDQZSHI-GHCJXIJMSA-N Ala-Ile-Asn Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(O)=O IFKQPMZRDQZSHI-GHCJXIJMSA-N 0.000 description 2
- SPWXXPFDTMYTRI-IUKAMOBKSA-N Asp-Ile-Thr Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(O)=O SPWXXPFDTMYTRI-IUKAMOBKSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 102000008203 CTLA-4 Antigen Human genes 0.000 description 2
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 2
- BYYNJRSNDARRBX-YFKPBYRVSA-N Gly-Gln-Gly Chemical compound NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(O)=O BYYNJRSNDARRBX-YFKPBYRVSA-N 0.000 description 2
- SOEGEPHNZOISMT-BYPYZUCNSA-N Gly-Ser-Gly Chemical compound NCC(=O)N[C@@H](CO)C(=O)NCC(O)=O SOEGEPHNZOISMT-BYPYZUCNSA-N 0.000 description 2
- 101000764263 Homo sapiens Tumor necrosis factor ligand superfamily member 4 Proteins 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 102000002698 KIR Receptors Human genes 0.000 description 2
- 108010043610 KIR Receptors Proteins 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 230000006044 T cell activation Effects 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- NUQZCPSZHGIYTA-HKUYNNGSSA-N Tyr-Trp-Gly Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)NCC(=O)O)NC(=O)[C@H](CC3=CC=C(C=C3)O)N NUQZCPSZHGIYTA-HKUYNNGSSA-N 0.000 description 2
- JVGHIFMSFBZDHH-WPRPVWTQSA-N Val-Met-Gly Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)O)N JVGHIFMSFBZDHH-WPRPVWTQSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 108010040443 aspartyl-aspartic acid Proteins 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 230000004940 costimulation Effects 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 210000003162 effector t lymphocyte Anatomy 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- XXQCMVYBAALAJK-UHFFFAOYSA-N ethyl n-[4-[benzyl(2-phenylethyl)amino]-2-(2-phenylethyl)-1h-imidazo[4,5-c]pyridin-6-yl]carbamate Chemical compound N=1C=2C(N(CCC=3C=CC=CC=3)CC=3C=CC=CC=3)=NC(NC(=O)OCC)=CC=2NC=1CCC1=CC=CC=C1 XXQCMVYBAALAJK-UHFFFAOYSA-N 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 208000005017 glioblastoma Diseases 0.000 description 2
- 108010001064 glycyl-glycyl-glycyl-glycine Proteins 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 238000002823 phage display Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000007480 sanger sequencing Methods 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 230000010473 stable expression Effects 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 102000003390 tumor necrosis factor Human genes 0.000 description 2
- IVLXQGJVBGMLRR-UHFFFAOYSA-N 2-aminoacetic acid;hydron;chloride Chemical compound Cl.NCC(O)=O IVLXQGJVBGMLRR-UHFFFAOYSA-N 0.000 description 1
- DKJPOZOEBONHFS-ZLUOBGJFSA-N Ala-Ala-Asp Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CC(O)=O DKJPOZOEBONHFS-ZLUOBGJFSA-N 0.000 description 1
- UGLPMYSCWHTZQU-AUTRQRHGSA-N Ala-Ala-Tyr Chemical compound C[C@H]([NH3+])C(=O)N[C@@H](C)C(=O)N[C@H](C([O-])=O)CC1=CC=C(O)C=C1 UGLPMYSCWHTZQU-AUTRQRHGSA-N 0.000 description 1
- ROLXPVQSRCPVGK-XDTLVQLUSA-N Ala-Glu-Tyr Chemical compound N[C@@H](C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O ROLXPVQSRCPVGK-XDTLVQLUSA-N 0.000 description 1
- LXAARTARZJJCMB-CIQUZCHMSA-N Ala-Ile-Thr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(O)=O LXAARTARZJJCMB-CIQUZCHMSA-N 0.000 description 1
- DYXOFPBJBAHWFY-JBDRJPRFSA-N Ala-Ser-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](C)N DYXOFPBJBAHWFY-JBDRJPRFSA-N 0.000 description 1
- MYTHOBCLNIOFBL-SRVKXCTJSA-N Asn-Ser-Tyr Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O MYTHOBCLNIOFBL-SRVKXCTJSA-N 0.000 description 1
- CGYKCTPUGXFPMG-IHPCNDPISA-N Asn-Tyr-Trp Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O CGYKCTPUGXFPMG-IHPCNDPISA-N 0.000 description 1
- XACXDSRQIXRMNS-OLHMAJIHSA-N Asp-Asn-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(=O)O)N)O XACXDSRQIXRMNS-OLHMAJIHSA-N 0.000 description 1
- QOVWVLLHMMCFFY-ZLUOBGJFSA-N Asp-Asp-Asn Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O QOVWVLLHMMCFFY-ZLUOBGJFSA-N 0.000 description 1
- 102000008096 B7-H1 Antigen Human genes 0.000 description 1
- 108010074708 B7-H1 Antigen Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 1
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- KCJJFESQRXGTGC-BQBZGAKWSA-N Gln-Glu-Gly Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(O)=O KCJJFESQRXGTGC-BQBZGAKWSA-N 0.000 description 1
- JXFLPKSDLDEOQK-JHEQGTHGSA-N Gln-Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CCC(N)=O JXFLPKSDLDEOQK-JHEQGTHGSA-N 0.000 description 1
- BUVMZWZNWMKASN-QEJZJMRPSA-N Glu-Asn-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(O)=O)N)C(O)=O)=CNC2=C1 BUVMZWZNWMKASN-QEJZJMRPSA-N 0.000 description 1
- IBYOLNARKHMLBG-WHOFXGATSA-N Gly-Phe-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CC1=CC=CC=C1 IBYOLNARKHMLBG-WHOFXGATSA-N 0.000 description 1
- CQMFNTVQVLQRLT-JHEQGTHGSA-N Gly-Thr-Gln Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(O)=O CQMFNTVQVLQRLT-JHEQGTHGSA-N 0.000 description 1
- JYGYNWYVKXENNE-OALUTQOASA-N Gly-Tyr-Trp Chemical compound [H]NCC(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O JYGYNWYVKXENNE-OALUTQOASA-N 0.000 description 1
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 description 1
- 102000037982 Immune checkpoint proteins Human genes 0.000 description 1
- 108091008036 Immune checkpoint proteins Proteins 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- PVMPDMIKUVNOBD-CIUDSAMLSA-N Leu-Asp-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O PVMPDMIKUVNOBD-CIUDSAMLSA-N 0.000 description 1
- WQWSMEOYXJTFRU-GUBZILKMSA-N Leu-Glu-Ser Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O WQWSMEOYXJTFRU-GUBZILKMSA-N 0.000 description 1
- UCDHVOALNXENLC-KBPBESRZSA-N Leu-Gly-Tyr Chemical compound CC(C)C[C@H]([NH3+])C(=O)NCC(=O)N[C@H](C([O-])=O)CC1=CC=C(O)C=C1 UCDHVOALNXENLC-KBPBESRZSA-N 0.000 description 1
- FLNPJLDPGMLWAU-UWVGGRQHSA-N Leu-Met-Gly Chemical compound OC(=O)CNC(=O)[C@H](CCSC)NC(=O)[C@@H](N)CC(C)C FLNPJLDPGMLWAU-UWVGGRQHSA-N 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 238000003725 ONE-Glo Luciferase Assay System Methods 0.000 description 1
- HNFUGJUZJRYUHN-JSGCOSHPSA-N Phe-Gly-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CC1=CC=CC=C1 HNFUGJUZJRYUHN-JSGCOSHPSA-N 0.000 description 1
- UXQFHEKRGHYJRA-STQMWFEESA-N Phe-Met-Gly Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCSC)C(=O)NCC(O)=O UXQFHEKRGHYJRA-STQMWFEESA-N 0.000 description 1
- AFNJAQVMTIQTCB-DLOVCJGASA-N Phe-Ser-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC1=CC=CC=C1 AFNJAQVMTIQTCB-DLOVCJGASA-N 0.000 description 1
- MVIJMIZJPHQGEN-IHRRRGAJSA-N Phe-Ser-Val Chemical compound CC(C)[C@@H](C([O-])=O)NC(=O)[C@H](CO)NC(=O)[C@@H]([NH3+])CC1=CC=CC=C1 MVIJMIZJPHQGEN-IHRRRGAJSA-N 0.000 description 1
- ZCXQTRXYZOSGJR-FXQIFTODSA-N Pro-Asp-Ser Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O ZCXQTRXYZOSGJR-FXQIFTODSA-N 0.000 description 1
- VYWNORHENYEQDW-YUMQZZPRSA-N Pro-Gly-Glu Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H]1CCCN1 VYWNORHENYEQDW-YUMQZZPRSA-N 0.000 description 1
- AWQGDZBKQTYNMN-IHRRRGAJSA-N Pro-Phe-Asp Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](CC(=O)O)C(=O)O AWQGDZBKQTYNMN-IHRRRGAJSA-N 0.000 description 1
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 1
- UBRXAVQWXOWRSJ-ZLUOBGJFSA-N Ser-Asn-Asp Chemical compound C([C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@H](CO)N)C(=O)N UBRXAVQWXOWRSJ-ZLUOBGJFSA-N 0.000 description 1
- XKFJENWJGHMDLI-QWRGUYRKSA-N Ser-Phe-Gly Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)NCC(O)=O XKFJENWJGHMDLI-QWRGUYRKSA-N 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 description 1
- YOPQYBJJNSIQGZ-JNPHEJMOSA-N Thr-Tyr-Tyr Chemical compound C([C@H](NC(=O)[C@@H](N)[C@H](O)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=C(O)C=C1 YOPQYBJJNSIQGZ-JNPHEJMOSA-N 0.000 description 1
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 1
- ICPRIGUXAFULPH-ILWGZMRPSA-N Trp-Tyr-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)N)C(=O)O ICPRIGUXAFULPH-ILWGZMRPSA-N 0.000 description 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
- 102100026890 Tumor necrosis factor ligand superfamily member 4 Human genes 0.000 description 1
- WPVGRKLNHJJCEN-BZSNNMDCSA-N Tyr-Asp-Phe Chemical compound C([C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=C(O)C=C1 WPVGRKLNHJJCEN-BZSNNMDCSA-N 0.000 description 1
- NQJDICVXXIMMMB-XDTLVQLUSA-N Tyr-Glu-Ala Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(O)=O NQJDICVXXIMMMB-XDTLVQLUSA-N 0.000 description 1
- AZSHAZJLOZQYAY-FXQIFTODSA-N Val-Ala-Ser Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O AZSHAZJLOZQYAY-FXQIFTODSA-N 0.000 description 1
- NZGOVKLVQNOEKP-YDHLFZDLSA-N Val-Phe-Asn Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(=O)N)C(=O)O)N NZGOVKLVQNOEKP-YDHLFZDLSA-N 0.000 description 1
- HTONZBWRYUKUKC-RCWTZXSCSA-N Val-Thr-Val Chemical compound CC(C)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O HTONZBWRYUKUKC-RCWTZXSCSA-N 0.000 description 1
- 208000037844 advanced solid tumor Diseases 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 229960003852 atezolizumab Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000012054 celltiter-glo Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229940000425 combination drug Drugs 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000017188 evasion or tolerance of host immune response Effects 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 102000051450 human TNFSF4 Human genes 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- PGHMRUGBZOYCAA-ADZNBVRBSA-N ionomycin Chemical compound O1[C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)/C=C/C[C@@H](C)C[C@@H](C)C(/O)=C/C(=O)[C@@H](C)C[C@@H](C)C[C@@H](CCC(O)=O)C)CC[C@@]1(C)[C@@H]1O[C@](C)([C@@H](C)O)CC1 PGHMRUGBZOYCAA-ADZNBVRBSA-N 0.000 description 1
- PGHMRUGBZOYCAA-UHFFFAOYSA-N ionomycin Natural products O1C(CC(O)C(C)C(O)C(C)C=CCC(C)CC(C)C(O)=CC(=O)C(C)CC(C)CC(CCC(O)=O)C)CCC1(C)C1OC(C)(C(C)O)CC1 PGHMRUGBZOYCAA-UHFFFAOYSA-N 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 108010044374 isoleucyl-tyrosine Proteins 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 238000012917 library technology Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 210000003071 memory t lymphocyte Anatomy 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 238000013492 plasmid preparation Methods 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 108010079317 prolyl-tyrosine Proteins 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 239000012557 regeneration buffer Substances 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 239000012146 running buffer Substances 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 229940126625 tavolimab Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 108091007466 transmembrane glycoproteins Proteins 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 108010020532 tyrosyl-proline Proteins 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Peptides Or Proteins (AREA)
Abstract
本发明公开了一种增强CAR‑T功能的合成纳米抗体及其制备方法和应用,所述抗体包括OX40 BC3‑1、OX40 BC3‑4、OX40 BC3‑6和OX40 BC3‑7中的至少一种序列,所述纳米抗体能够特异性结合OX40抗原,且具有很高的亲和力和显著的抗肿瘤作用,并且还可以增强CAR‑T的功能。
Description
技术领域:
本发明涉及一种抗体及其制备方法和应用,具体涉及一种可以增强嵌合抗原受体T细胞免疫疗法(CAR-T)的功能的抗OX40合成纳米抗体及其制备方法和应用。
背景技术:
免疫治疗目前被认为是癌症治疗的主要替代方法之一。特别是,免疫疗法通过抑制或激活一些免疫检查点,例如PD-1/PD-L1通路(程序性细胞死亡蛋白1/程序性细胞死亡1配体1,CTLA-4(细胞毒性T淋巴细胞抗原4),LAG-3(淋巴细胞活化基因)、OX40、TIM-3(T细胞免疫球蛋白和粘蛋白结构域3)、KIR(杀伤细胞免疫球蛋白样受体)和TIGIT(T细胞免疫球蛋白和ITIM结构域)来逆转肿瘤的免疫逃逸。
OX40,又称CD134、TNFRSF4或ACT35,是一种在CD4+和CD8+T细胞以及中性粒细胞和NK细胞中表达的膜蛋白,属于肿瘤坏死因子受体/肿瘤坏死因子超家族成员,编码一种50kDd的I型跨膜糖蛋白。胞外区有191个氨基酸,包含了三个完整的以及一个稍短的富含半胱氨酸结构域(CRDs)。OX40是T细胞表面的正性共刺激分子,不表达于静止的T细胞表面,而在T细胞活化24-72小时有较高的表达,与其配体OX40L(又称CD252或TNFSF4)结合传递共刺激信号。OX40/OX40L信号在T细胞的活化、增值以及抑制凋亡过程中发挥着非常重要的作用。有研究表明,OX40通过各种信号途径,如NF-κB途径,引起细胞因子的大量产生,并产生记忆和效应T细胞。在非小细胞肺癌、卵巢癌、进展期胃癌,晚期结直肠癌、黑色素瘤和胶质母细胞瘤中,肿瘤免疫浸润中OX40的高表达与良好的预后有关。OX40激动剂免疫治疗可提高胶质母细胞瘤小鼠的存活率,防止卵巢癌中的肿瘤生长,并增加CD8+细胞浸润结直肠癌的预后意义。与OX40对T效应细胞(Teff)的共刺激作用相反,OX40共刺激消除了组成性表达OX40的Foxp3+Treg细胞的抑制功能。在一些动物模型中,OX40衍生信号显著抑制活化T效应细胞诱导新的Foxp3+Treg细胞。因此,OX40可能是外周Foxp3+Treg细胞的一个强有力的负调节因子。
综上所述,OX40激活效应T细胞并抑制调节T细胞,正向调控刺激肿瘤免疫,基于这些特点,OX40受体被广泛认为是新型肿瘤免疫治疗最有希望的靶点之一。
除其配体OX40L外,目前已有多种激动剂抗体亦可介导OX40的激活,例如pogalizumab,一种人源化IgG1单克隆OX40抗体已在临床(NCT02410512)上与atezolizumab联合用于晚期实体瘤的治疗,初期结果显示出良好的依从性。此外,还有例如Medi0562,IBI101和BGB-A445等激动剂抗体也纷纷进入临床阶段用于各种肿瘤的治疗。
尽管CAR-T在治疗血液癌症方面取得了成功,但它并不那么容易消除实体瘤。实体瘤通常在高度免疫抑制的环境中发展并且难以靶向,原因之一是肿瘤为环境的免疫抑制,使得T细胞失活。
2017年,美国食品药品管理局(FDA)批准了涉及CAR-T的治疗方法:来自患者的T细胞经基因改造后识别癌细胞表面上的特定蛋白,然后将这些经过基因改造的T细胞灌注到相同的患者体内,它们会对癌细胞产生靶向性免疫反应。CAR-T细胞已经成功地用于治疗白血病和淋巴瘤等血癌,而且往往取得了显著的效果,然而,这些治疗方法对实体瘤的成功率很低。当CAR-T细胞进入实体瘤时,它们很快就会失去功能。这种称为“衰竭”的状态伴随着它们表面上的PD1等免疫抑制蛋白增加,并且无法产生如干扰素γ和肿瘤坏死因子,使得CAR-T失去对肿瘤杀伤的能力。找到一种防止CAR-T细胞衰竭的方法已经成为癌症研究的重要目标。
基于上述研究,该申请通过噬菌体表面展示合成抗体库技术,制备了抗OX40的激动剂纳米抗体,可结合细胞表面的OX40,有效促进T细胞的活化和增值,发挥较好的抗肿瘤活性。此外,激活型的OX40抗体也能够增强CAR-T的功能,有望作为肿瘤免疫细胞治疗CAR-T的联用药物。
发明内容:
本发明的目的在于,解决上述现有技术的不足,利用噬菌体展示技术,合成噬菌体纳米抗体库,制备出一种靶向OX40的人源化纳米抗体,所述纳米抗体能够特异性结合OX40抗原,且具有很高的亲和力和显著的抗肿瘤作用,并且还可以增强CAR-T的功能。为实现上述目的,本发明采用以下技术方案:
本发明公开了一种增强CAR-T功能的合成纳米抗体,具体序列如下:
抗体号 | VHH序列 |
OX40 BC3-1 | SEQ ID NO.1 |
OX40 BC3-4 | SEQ ID NO.2 |
OX40 BC3-6 | SEQ ID NO.3 |
OX40 BC3-7 | SEQ ID NO.4 |
本发明还公开了一种制备所述增强CAR-T功能的合成纳米抗体的方法,包括以下具体步骤:
1.噬菌体展示合成纳米抗体库的筛选:
(1)将OX40-mFc蛋白包被于96孔Nunc Maxisorp免疫板上,4℃过夜;优选OX40-mFc蛋白的浓度为30ug/mL,溶剂为磷酸盐缓冲生理盐水,100μL/孔,4孔/文库;
(2)用质量比为2%的脱脂牛奶(在磷酸盐缓冲生理盐水中)室温封闭2小时后,磷酸盐缓冲生理盐水洗涤液清洗2-4次;
(3)每个文库取约1013个噬菌体(溶解于2%脱脂牛奶,溶剂为磷酸盐缓冲生理盐水洗涤液),加入至4个包被孔中,室温震荡孵育2小时;
(4)用磷酸盐缓冲生理盐水洗涤液清洗包被板10次,然后每孔加入100μL100mMHCl,室温震荡洗脱5分钟后,吸出洗脱液至EP管中,并加入1/8体积的1.0M Tris-HCl(pH 11)进行中和;
(5)用洗脱的噬菌体侵染3mL处于对数生长期的大肠杆菌SS320(OD600不超过1.0),37℃,220rpm培养30分钟后取出200μL侵染产物保存,向剩余菌液加入M13KO7辅助噬菌体(终浓度至1010个/mL)继续培养1小时;
(6)将上述培养液转移接种至50mL 2YT培养基(Carb+,Kan+)中,37℃,220rpm过夜培养。
(7)重复步骤(1)至步骤(6)进行第二轮和第三轮的筛选
2.阳性克隆的分离与鉴定
(1)三轮筛选后将第二、三轮的侵染产物分别涂布到LB/Carb+平板上37℃过夜培养;
(2)次日挑菌至2YT/Carb+/辅助噬菌体(1010个/mL)中过夜培养;
(3)用ELISA方法鉴定单克隆培养上清中噬菌体与OX40-mFc的结合力强弱,挑选阳性克隆进行Sanger测序。
3.VHH-Fc抗体表达和纯化
用PCR方法将步骤2中得到的阳性克隆VHH基因从噬菌体上清中扩增出来,用Takara In-Fusion克隆试剂盒融合至带有linker+hIgG1的细胞表达载体上,将构建好的质粒转染ExpiCHO细胞,进行分泌表达。收获的细胞上清用蛋白A柱子进行亲和纯化得到带有Fc端的VHH-Fc完整纳米抗体。较佳的,上述载体中的linker序列为SEQ ID NO.5。
本发明还公开了所述增强CAR-T功能的合成纳米抗体的应用方法,包括以下具体步骤:
1.OX40 VHH-Fc抗体与OX40稳转细胞株的特异性结合:
(1)表达OX40蛋白的稳定细胞株的构建;
(2)流式特异性结合试验(FACS)检测抗体与L929细胞株稳定表达OX40蛋白的结合;
(3)流式特异性结合试验(FACS)检测抗体与Jurkat细胞株稳定表达OX40蛋白的结合。
2.OX40VHH-Fc抗体对NF-kB信号通路的有效激活:
(1)Jurkat/NF-kB-Luc-hOX40稳定细胞系的构建;
(2)L929-CD32b稳定细胞系的构建;
(3)NF-kB报告基因实验。
3.通过表面等离子共振(SPR)分析抗OX40抗体与hOX40的动力学亲和力常数;
4.抗人OX40抗体对OX40和OX40L蛋白结合的抑制作用;
(1)通过报告基因法检测抗人OX40抗体对OX40和OX40L蛋白结合的抑制作用;
(2)通过流式检测法(FACS)检测抗人OX40抗体对OX40和OX40L蛋白结合的抑制作用。
本发明的优点是:1.本发明以有效展示所获得的OX40抗体与OX40抗原,OX40L及相关稳转细胞系的特异性结合作用,验证其对NF-kB信号通路的激活效果,证明本发明所获得的OX40VHH-Fc纳米抗体具有皮摩尔级别的亲和力和显著的抗肿瘤等作用活性,最高能增强约60%的CAR-T活性。
附图说明:
图1为L929-hOX40细胞株的人OX40表达的FACS分析结果;
图2为Jurkat-hOX40细胞株的人OX40表达的FACS分析结果;
图3为FACS检测抗OX40纳米抗体与L929-hOX40细胞株的结合反应的结果;
图4为FACS检测抗OX40纳米抗体与Jurkat-hOX40细胞株的结合反应的结果;
图5为使用荧光素酶方法检测Jurkat/NFkB-Luc-hOX40稳转细胞株经PMA/Ionomycin刺激后NFkB RE-Luciferase的表达水平的结果;
图6为FACS检测Jurkat/NFkB-Luc-hOX40稳转细胞株hOX40的表达水平的结果;
图7为FACS检测L929-hCD32b稳转细胞株hCD32b的表达水平的结果;
图8为NFkB报告基因实验检测抗OX40纳米抗体对NFkB信号通路的激活作用的结果;
图9为使用NFkB报告基因方法,检测Jurkat/NFkB-Luc-hOX40稳转细胞株中抗OX40纳米抗体与hOX40L竞争结合人OX40蛋白的结果;
图10为FACS检测L929-OX40细胞株中OX40纳米抗体与hOX40L竞争结合人OX40蛋白的结果;
图11为OX40纳米抗体增加CAR-T对N87细胞杀伤的结果:靶细胞(N87-Luc)效靶比=1∶5,48小时。
具体实施方式:
实施例1:OX40 VHH-Fc纳米抗体的制备
1.噬菌体抗体库的筛选
(1)将OX40-mFc蛋白(30ug/mLin磷酸盐缓冲生理盐水,100μL/孔,4孔/文库)包被于96孔Nunc Maxisorp免疫板上,4℃过夜;
(2)用2%脱脂牛奶(in磷酸盐缓冲生理盐水)室温封闭2小时后,磷酸盐缓冲生理盐水洗涤液清洗2-4次;
(3)每个文库取约1013个噬菌体(溶解于2%脱脂牛奶in磷酸盐缓冲生理盐水洗涤液),加入至4个包被孔中,室温震荡孵育2小时。
(4)用磷酸盐缓冲生理盐水洗涤液清洗包被板10次,然后每孔加入100μL100mMHCl,室温震荡洗脱5分钟后,吸出洗脱液至EP管中,并加入1/8体积的1.0M Tris-HCl(pH 11)进行中和;
(5)用洗脱的噬菌体侵染3mL处于对数生长期的SS320(OD600不超过1.0),37℃,220rpm培养30分钟后取出200μL侵染产物保存,向剩余菌液加入M13KO7辅助噬菌体(终浓度至1010个/mL)继续培养1小时。
(6)将上述培养液转移接种至50mL 2YT培养基(Carb+,Kan+)中,37℃,220rpm过夜培养。
(7)重复步骤(1)至步骤(6)进行第二轮和第三轮的筛选。
(8)三轮筛选后将第二、三轮的侵染产物分别涂布到LB/Carb+平板上37℃过夜培养;
(9)次日挑菌至2YT/Carb+/辅助噬菌体(1010个/mL)中过夜培养。
(10)用ELISA方法鉴定单克隆培养上清中噬菌体与OX40-mFc的结合力强弱,挑选阳性克隆进行Sanger测序。
通过三个批次的重复筛选(每个批次筛选3轮),共得到4个不同的阳性克隆序列(见表1)。
表1
2.VHH-Fc抗体表达纯化
用PCR方法将20个阳性克隆VHH基因从噬菌体上清中扩增出来,用Takara In-Fusion克隆试剂盒融合至带有linker+hIgG1的细胞表达载体上。将构建好的质粒转染ExpiCHO细胞,进行分泌表达。
收获的细胞上清用蛋白A柱子进行亲和纯化,得到上述20种靶向OX40的人源化纳米抗体。
实施例2:OX40 VHH-Fc抗体与OX40稳转细胞株的特异性结合
1.表达OX40蛋白的稳定细胞株的构建:
将编码人源OX40全长氨基酸序列的核苷酸序列克隆到质粒载体并进行质粒制备。对L929和Jurkat细胞系分别进行hOX40质粒转染,分别在含500ug/mL潮霉素(Hygromycin)的DMEM+10%FBS和RPMI1640+10%FBS培养液中选择性培养,一周后挑取存活的细胞,用有限稀释法在96孔培养板中进行克隆,大约2周后选择部分单克隆扩增至24孔板中,并在大约3~4天后扩增至6孔板中。对扩增后的单克隆用抗人OX40抗体经流式检测进行筛选。选择长势较好,荧光强度较高,单克隆的细胞系继续扩大培养(潮霉素减半)并液氮冻存,最终得到表达人OX40蛋白的L929和Jurkat稳定细胞株(此处称L929-hOX40和Jurkat-hOX40稳定细胞株)。图1和图2表明,已经筛选得到稳定表达人OX40的L929和Jurkat稳定细胞株。
2.流式特异性结合试验(FACS)检测抗体与L929细胞株稳定表达OX40蛋白的结合
将上述构建的L929-hOX40稳定细胞株在细胞培养瓶中扩大培养至90%汇合度,磷酸盐缓冲液(磷酸盐缓冲生理盐水)洗涤后,用0.25%Trypsin(购自Thermofisher)消化至单个细胞悬液,用含10%FBS培养液进行中和后,进行计数。1000rpm离心5分钟后用FACS缓冲液(磷酸盐缓冲生理盐水+1%FBS)重悬至2×106细胞/mL,按照每孔200μL加入96孔FACS培养板中,1000rpm离心5分钟后去上清,加入一系列浓度梯度的抗人OX40纯化待测抗体,每孔200μL,4℃避光孵育1小时,1000rpm离心5分钟后加入每孔200μLPE荧光标记的anti-human FC二抗(购自Invitrogen),4℃避光孵育1小时。用FACS缓冲液洗涤2次,加入每孔200μL含1%多聚甲醛的磷酸盐缓冲生理盐水缓冲液重悬细胞,用FACS仪器(BD Accuri C6)进行检测和分析。结果如图3所示,抗人OX40待测抗体可特异性结合细胞表面的hOX40蛋白。其中Isotype为抗体亚型人源对照IgG,图中的MFI为所测细胞群的平均荧光强度值。表2为抗体与L929细胞株稳定表达OX40蛋白的结合。
表2
No. | Sample ID | Max Value | EC50(pM) |
1 | Isotype Control | 8957 | / |
2 | BC3-1 | 284630 | 488.2 |
3 | BC3-4 | 307936 | 861.9 |
4 | BC3-6 | 198371 | 545.2 |
5 | BC3-7 | 327102 | 692.6 |
6 | MoxR-0916 | 453233 | 570.0 |
3.流式特异性结合试验(FACS)检测抗体与Jurkat细胞株稳定表达OX40蛋白的结合
将1中构建的Jurkat-hOX40稳定细胞株在细胞培养瓶中扩大培养,取对数生长期的细胞进行计数。1000rpm离心5分钟后用FACS缓冲液(磷酸盐缓冲生理盐水+1%FBS)重悬至2×106细胞/mL,按照每孔200μL加入96孔FACS培养板中,1000rpm离心5分钟后去上清,加入一系列浓度梯度的抗人OX40纯化待测抗体,每孔200μL,4℃避光孵育1小时,1000rpm离心5分钟后加入每孔200μLPE荧光标记的抗人FC二抗(购自Invitrogen),4℃避光孵育1小时。用FACS缓冲液洗涤2次,加入每孔200μL含1%多聚甲醛的磷酸盐缓冲生理盐水缓冲液重悬细胞,用FACS仪器(BD Accuri C6)进行检测和分析。结果如图4所示,抗人OX40待测抗体可特异性结合细胞表面的hOX40蛋白。其中Isotype为抗体亚型人源对照IgG,图中的MFI为所测细胞群的平均荧光强度值。表3为抗体与Jurkat细胞株稳定表达OX40蛋白的结合。
表3
No. | Sample ID | Max Value | EC50(pM) |
1 | Isotype Control | 998.7 | / |
2 | BC3-1 | 17457 | 256.5 |
3 | BC3-4 | 23969 | 394.7 |
4 | BC3-6 | 12806 | 682.8 |
5 | BC3-7 | 24120 | 548.4 |
6 | MoxR-0916 | 30215 | 298.5 |
实施例3:OX40 VHH-Fc抗体有效激活NF-kB信号通路
1.Jurkat/NFkB-Luc-hOX40稳定细胞系的构建
将pGL4.32[luc2P/NF-kB-RE/Hygro]质粒(购自Promega)转染至Jurkat细tu得到稳定表达NF-kB-RE-Luc的Jurkat细胞株(此处称为Jurkat/NF-kB-Luc)。
构建OX40慢病毒质粒,包装慢病毒后感染Jurkat-NF-kB-Luc细胞,同时用含潮霉素(Hygromycin)和10%FBS的RPMI1640培养液进行培养,筛选得到稳定表达NF-kB-RE-Luc和OX40的Jurkat细胞株(此处称为Jurkat/NF-kB-Luc-hOX40)。图5为NF-Kb报告基因的实验结果,表明筛选得到的Jurkat/NF-kB-Luc-hOX40细胞株稳定表达NF-kB-RE荧光素酶(Luciferase)。图6为FACS检测结果,表明筛选得到的Jurkat/NF-kB-Luc-hOX40细胞株稳定表达hOX40。
2.L929-CD32b稳定细胞系的构建
对L929细胞系进行hCD32b质粒转染,在含600ug/ml潮霉素(Hygromycin)的DMEM+10%FBS培养基中选择性培养,挑取存活的细胞进行克隆,用有限稀释法在96孔培养板中进行亚克隆,大约2周后选择部分单克隆扩增至24孔板中,并在大约3~4天后扩增至6孔板中。对扩增后的克隆用CD32b抗体(购自Stemcell)经流式检测进行筛选。图7为FACS检测结果,表明筛选得到的L929-hCD32b细胞株稳定表达hCD32b。
3.NF-kB报告基因实验
将步骤2中筛选得到的L929-hCD32b细胞扩大培养,收集后用含10%FBS的DMEM培养液重悬,将细胞以2×104/孔的密度接种于96孔培养板中。过夜后弃去上清,以5×104/孔的细胞密度加入实例3.1筛选得到的Jurkat/NF-kB-Luc-hOX40细胞,再加入一系列浓度梯度的抗人OX40待测抗体,放入CO2细胞培养箱中继续培养5小时。用ONE-Glo荧光素酶检测系统(购自Promega)测定荧光素酶的含量。结果如图8所示,表明所述抗人OX40待测抗体能显著激活NF-kB信号通路。表4为抗人OX40待测抗体激活NF-kB信号通路。
表4
No. | Sample ID | Max Value | EC50(pM) |
1 | Isotype Control | 2650 | / |
2 | BC3-1 | 53365 | 209.2 |
3 | BC3-4 | 55747 | 175.1 |
4 | BC3-6 | 50273 | 162.4 |
5 | BC3-7 | 48390 | 129.8 |
6 | MoxR-0916 | 29821 | 216.9 |
实施例4:通过表面等离子共振(SPR)分析抗OX40抗体与hOX40的动力学亲和力常数
抗人OX40抗体对针对重组的人OX40的结合动力学通过表面等离子共振(surface/plasmon resonance,SPR)方法,使用Biacore 8K仪器(序列号29327020-2473040,GE)实时检测反应信号,以获得结合和解离曲线。蛋白A芯片(目录号29127556,GE)偶联人his标签OX40抗原,将抗人OX40待测抗体用runningbuffer稀释至90-5.62nM,二倍梯度稀释共5个浓度点。进样时间为180秒,解离时间为1800s,再生时间为60秒,缓冲液为HBS-EP+,再生buffer为10nM glycine-HCl(pH1.5)。使用简单一对一Languir结合模型(Biacore评价软件3.0版InsightEvaluation Software v3.0)计算结合速率(Kon)和解离速率(Koff)。平衡解离常数(kD)以比率koff/kon计算。结果请详见表5。表5为抗人OX40待测抗体与hOX40结合动力学检测。
表5
NO. | Sample ID | ka(1/Ms) | kd(1/s) | KD(M) |
1 | MoxR-0916 | 5.41E+5 | 1.30E-4 | 2.40E-10 |
2 | BC3-1 | NA | NA | NA |
3 | BC3-4 | 2.87E+5 | 2.38E-2 | 8.29E-08 |
4 | BC3-6 | NA | NA | NA |
5 | BC3-7 | 3.27E+5 | 3.59E-3 | 1.10E-08 |
实施例5:抗人OX40抗体对OX40和OX40L蛋白结合的抑制作用
1.通过报告基因法检测抗人OX40抗体对OX40和OX40L蛋白结合的抑制作用
取实施例3步骤1中构建的筛选得到的Jurkat/NF-kB-Luc-hOX40细胞,以5×104/孔的细胞密度加入96孔细胞培养板中,稀释人OX40L蛋白至0.3ug/ml浓度和一系列梯度稀释的抗人OX40待测抗体同时加入细胞,在CO2培养箱中孵育5小时后进行荧光素酶含量测定。结果如图9所示,表明抗人OX40待测抗体可在不同程度上抑制OX40L与OX40的结合,进一步表明待测抗体与OX40L存在表位竞争关系。
2.通过流式检测法(FACS)检测抗人OX40抗体对OX40和OX40L蛋白结合的抑制作用
将实施例2步骤1中构建的L929-hOX40稳定细胞株在细胞培养瓶中扩大培养至90%汇合度,磷酸盐缓冲生理盐水磷酸盐缓冲液洗涤后,用0.25%Trypsin(购自Thermofisher)消化至单个细胞悬液,用含10%FBS培养液进行中和后,并进行计数。1000rpm离心5分钟后用FACS缓冲液(磷酸盐缓冲生理盐水+1%FBS)重悬至2×106细胞/mL,按照每孔200μL加入96孔FACS培养板中,1000rpm离心5分钟后弃上清,同时加入0.5ug/ml浓度的抗人OX40待测抗体和一系列梯度稀释的OX40L蛋白,4℃避光孵育1小时,1000rpm离心5分钟后加入每孔200μLPE荧光标记的抗人FC二抗(购自Invitrogen),4℃避光孵育1小时。用FACS缓冲液洗涤2次,每孔加入200μL含1%多聚甲醛的磷酸盐缓冲生理盐水缓冲液重悬细胞,用FACS仪器(BD Accuri C6)进行检测和分析。
结果如图10所示,表明抗人OX40待测抗体和OX40L竞争与OX40的结合,结合报告基因OX40抑制实验验证抗OX40的待测抗体与OX40L存在表位竞争关系。
实施例6:抗人OX40抗体对CAR-T毒性的增强作用
我们接下来研究OX40抗体对CAR-T功能的影响。将N87靶向的CAR-T细胞与N87乳腺癌细胞共培养48小时(效靶比1∶5),同时加入磷酸盐缓冲生理盐水或10nM的OX40抗体(BC3-1,BC3-4,BC3-6,BC3-7)。然后用磷酸盐缓冲生理盐水将T细胞从板中洗出,使用Cell TiterGlo测定法(Promega)测量剩余的活N87细胞检测CAR-T的细胞毒性。我们发现OX40抗体可以增强CAR-T对N87细胞的毒性(图11)。
序列表
<110> 上海润诺生物科技有限公司
<120> 一种增强CAR-T 功能的合成纳米抗体及其制备方法和应用
<160> 5
<170> SIPOSequenceListing 1.0
<210> 1
<211> 118
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 1
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Ser Ile Phe Ser Val Tyr
20 25 30
Val Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Gly Arg Glu Leu Val
35 40 45
Ala Ala Ile Thr Pro Phe Asp Asp Asn Thr Tyr Tyr Pro Asp Ser Val
50 55 60
Glu Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Arg Met Val Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Ala Ser Ala Glu Tyr Pro Gly Glu Asn Tyr Trp Gly Gln Gly Thr
100 105 110
Gln Val Thr Val Ser Ser
115
<210> 2
<211> 118
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 2
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ile Phe Ser Ala Tyr
20 25 30
Phe Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Gly Arg Glu Leu Val
35 40 45
Ala Ala Ile Asn Ser Asn Asp Asp Ile Thr Tyr Tyr Pro Asp Ser Val
50 55 60
Glu Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Arg Met Val Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Ala Tyr Leu Gly Tyr Glu Asn Trp Gly Tyr Trp Gly Gln Gly Thr
100 105 110
Gln Val Thr Val Ser Ser
115
<210> 3
<211> 124
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 3
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Ser Ile Leu Asp Ser Asn
20 25 30
Leu Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Gly Arg Glu Leu Val
35 40 45
Ala Ser Ile Asn Ser Tyr Asp Asp Asn Thr Tyr Tyr Pro Asp Ser Val
50 55 60
Glu Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Arg Met Val Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Ala Ser Val Phe Asn Trp Tyr Pro Tyr Glu Ala Gln Glu Gly Asp
100 105 110
Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser
115 120
<210> 4
<211> 120
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 4
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Ser Ile Tyr Asp Phe Asp
20 25 30
Val Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Gly Arg Glu Leu Val
35 40 45
Ala Ala Ile Asn Ser Phe Gly Asp Ile Thr Tyr Tyr Pro Asp Ser Val
50 55 60
Glu Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Arg Met Val Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Ala Asp Phe Gly Val Leu Glu Ser Val Ala Ser Tyr Trp Gly Gln
100 105 110
Gly Thr Gln Val Thr Val Ser Ser
115 120
<210> 5
<211> 12
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 5
Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
1 5 10
Claims (2)
1.一种靶向 OX40 的合成纳米抗体,其特征在于,包括以下序列中的一种: SEQ IDNO.2和SEQ ID NO.4。
2.如权利要求1所述的一种靶向 OX40 的合成纳米抗体,其性能参数的测试方法包括以下具体步骤:
a. OX40 VHH-Fc抗体与OX40稳转细胞株的特异性结合:
(1)表达OX40蛋白的稳定细胞株的构建;
(2)流式特异性结合试验检测抗体与L929细胞株稳定表达OX40蛋白的结合;
(3)流式特异性结合试验检测抗体与Jurkat细胞株稳定表达OX40蛋白的结合;
b. OX40 VHH-Fc抗体对NF-kB信号通路的有效激活:
(1)Jurkat/NF-kB-Luc-hOX40稳定细胞系的构建;
(2)L929-CD32b稳定细胞系的构建;
(3)NF-kB报告基因实验;
c 通过表面等离子共振分析抗OX40抗体与hOX40的动力学亲和力常数;
d. 抗人OX40抗体对OX40和OX40L蛋白结合的抑制作用;
(1)通过报告基因法检测抗人OX40抗体对OX40和OX40L蛋白结合的抑制作用;
(2)通过流式检测法检测抗人OX40抗体对OX40和OX40L蛋白结合的抑制作用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210733760.8A CN114920844B (zh) | 2022-06-27 | 2022-06-27 | 一种增强car-t功能的合成纳米抗体及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210733760.8A CN114920844B (zh) | 2022-06-27 | 2022-06-27 | 一种增强car-t功能的合成纳米抗体及其制备方法和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114920844A CN114920844A (zh) | 2022-08-19 |
CN114920844B true CN114920844B (zh) | 2023-12-29 |
Family
ID=82813713
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210733760.8A Active CN114920844B (zh) | 2022-06-27 | 2022-06-27 | 一种增强car-t功能的合成纳米抗体及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114920844B (zh) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104341388A (zh) * | 2013-10-16 | 2015-02-11 | 上海润诺生物科技有限公司 | 芳香族酰胺类衍生物、其制备方法及其在医药上的应用 |
WO2020103836A1 (zh) * | 2018-11-20 | 2020-05-28 | 上海开拓者生物医药有限公司 | Ox40抗体及其制备方法和应用 |
CN112794907A (zh) * | 2020-12-03 | 2021-05-14 | 安徽安科生物工程(集团)股份有限公司 | 一株全人源抗人huOX40单克隆抗体 |
CN114656564A (zh) * | 2021-12-20 | 2022-06-24 | 安徽安科生物工程(集团)股份有限公司 | 一种抗hu-OX40抗原的纳米抗体及其应用 |
-
2022
- 2022-06-27 CN CN202210733760.8A patent/CN114920844B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104341388A (zh) * | 2013-10-16 | 2015-02-11 | 上海润诺生物科技有限公司 | 芳香族酰胺类衍生物、其制备方法及其在医药上的应用 |
WO2020103836A1 (zh) * | 2018-11-20 | 2020-05-28 | 上海开拓者生物医药有限公司 | Ox40抗体及其制备方法和应用 |
CN112794907A (zh) * | 2020-12-03 | 2021-05-14 | 安徽安科生物工程(集团)股份有限公司 | 一株全人源抗人huOX40单克隆抗体 |
CN114656564A (zh) * | 2021-12-20 | 2022-06-24 | 安徽安科生物工程(集团)股份有限公司 | 一种抗hu-OX40抗原的纳米抗体及其应用 |
Non-Patent Citations (2)
Title |
---|
OX40/OX40L在免疫应答中的作用及与疾病关系的研究进展;许香广;;中国实用医药(第14期);第145-147页 * |
一株抗人OX40激发型单克隆抗体的研制及其生物学功能的初步研究;毛辉等;《现代免疫学》;第30卷(第3期);第195-201页 * |
Also Published As
Publication number | Publication date |
---|---|
CN114920844A (zh) | 2022-08-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109096396B (zh) | 一种抗pd-l1人源化纳米抗体及其应用 | |
CN109734813B (zh) | 一种嵌合抗原受体及其应用 | |
JP6845846B6 (ja) | 抗ヒトcd137の完全ヒト抗体及びその用途 | |
RU2753882C2 (ru) | Трифункциональная антигенсвязывающая молекула | |
CN112142842B (zh) | 抗PD-L1纳米抗体及其Fc融合蛋白和应用 | |
CN109503716B (zh) | 一种双特异性嵌合抗原受体分子及其在肿瘤治疗上的应用 | |
CN108341871A (zh) | 抗pd-1单克隆抗体及其制备方法和应用 | |
JP2021526012A (ja) | Ctla−4を標的とする抗体、その調製方法および使用 | |
KR20210050535A (ko) | 항-bcma 단일 도메인 항체 및 그 적용 | |
KR20210013691A (ko) | 수정된 링커 도메인을 갖는 키메라 항원 수용체 및 그 용도 | |
CN113444178B (zh) | 抗cd70内化的抗体、抗体偶联物及其应用 | |
WO2023001154A1 (zh) | 一种b7-h3抗体及其应用 | |
CN114181296B (zh) | 一种高亲和力的pd-1膜外区突变体的融合蛋白及其药物组合物和用途 | |
CN112521513B (zh) | 一种靶向cd19的嵌合抗原受体(car)及其应用 | |
CN112679618B (zh) | 一种靶向trbc1的人源化嵌合抗原受体、t细胞及用途 | |
CN114920844B (zh) | 一种增强car-t功能的合成纳米抗体及其制备方法和应用 | |
CN115960233B (zh) | 一种抗cd22的纳米抗体及其制备方法和应用 | |
CN112442126B (zh) | 一种抗人cs1抗原的单克隆抗体及其car-t细胞 | |
CN114075287A (zh) | 人源化bcma抗体和bcma-car-t细胞 | |
CN112457416B (zh) | 一种靶向bcma的嵌合抗原受体(car)及其应用 | |
WO2024088371A1 (zh) | 靶向msln的抗原结合蛋白 | |
WO2023134718A1 (zh) | 靶向gprc5d的嵌合抗原受体及其用途 | |
US20240174768A1 (en) | Bispecific antibodies enhancing cell mediated immune responses | |
CN117003851A (zh) | 一种白细胞介素-2突变蛋白 | |
CN115611984A (zh) | NKp46抗体及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |